股本结构
单位：万股
| 公告日期 | 2026-02-26 | 2026-02-26 | 2025-10-29 | 2025-10-29 | 2025-07-31 | 2025-07-31 |
|---|---|---|---|---|---|---|
| 证券总股本 | 75906.73 | 75906.75 | 76770.13 | 76870.16 | 79378.28 | 77978.31 |
| 普通股本 | 75906.73 | 75906.75 | 76770.13 | 76870.16 | 79378.28 | 77978.31 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-01-30 | 2025-12-31 | 2025-10-17 | 2025-09-30 | 2025-07-21 | 2025-06-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-02-26 | 75906.73 | 未披露 | 定期报告 | 2026-01-30 |
| 2026-02-26 | 75906.75 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Exercise of common stock options/vesting of restricted stock units
Repurchase of 2029 Convertible Notes
Shares repurchase
|
2025-12-31 |
| 2025-10-29 | 76770.13 | 未披露 | 定期报告 | 2025-10-17 |
| 2025-10-29 | 76870.16 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Share repurchase
|
2025-09-30 |
| 2025-07-31 | 79378.28 | 未披露 | 定期报告 | 2025-07-21 |
| 2025-07-31 | 77978.31 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Repurchase of 2029 Convertible Notes
Exercise of common stock options and vested restricted stock units
Share repurchase
|
2025-06-30 |
| 2025-05-01 | 79305.28 | 未披露 | 定期报告 | 2025-04-15 |
| 2025-05-01 | 67160.68 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Exercise of common stock options
|
2025-03-31 |
| 2025-03-14 | 67160.15 | 未披露 | 定期报告 | 2025-02-24 |
| 2025-03-03 | 67155.03 | 未披露 | 定期报告 | 2025-01-31 |
| 2025-03-03 | 67155.05 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Exercise of common stock options/vesting of restricted stock units
Shares repurchase
2025 Notes
|
2024-12-31 |
| 2024-11-15 | 67280.03 | 未披露 | 定期报告 | 2024-11-13 |
| 2024-11-07 | 68248.30 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Share repurchase
|
2024-09-30 |
| 2024-08-29 | 69198.68 | 未披露 | 定期报告 | 2024-08-27 |
| 2024-08-07 | 69737.61 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Exercise of common stock options and warrants
2025 convertible notes
|
2024-06-30 |
| 2024-05-07 | 69699.17 | 未披露 | 定期报告 | 2024-05-03 |
| 2024-05-07 | 69701.91 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
2025 convertible notes
Share Repurchase
|
2024-03-31 |
| 2024-02-29 | 69699.17 | 未披露 | 定期报告 | 2024-02-13 |
| 2024-03-01 | 69699.17 | 未披露 | 定期报告 | 2024-01-31 |
| 2024-03-01 | 77328.18 | 未披露 |
更多>>
From December 31,2022 to December 31,2023
Exercise of common stock options and warrants
|
2023-12-31 |
| 2023-11-06 | 77305.65 | 未披露 | 定期报告 | 2023-11-01 |
| 2023-11-06 | 77305.68 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Exercise of common stock options and warrants
|
2023-09-30 |
| 2023-08-03 | 77305.65 | 未披露 | 定期报告 | 2023-07-27 |
| 2023-08-03 | 77303.81 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Exercise of common stock options and warrants
|
2023-06-30 |
| 2023-05-03 | 77265.08 | 未披露 | 定期报告 | 2023-04-27 |
| 2023-05-03 | 77265.11 | 未披露 | 定期报告 | 2023-03-31 |
| 2023-02-21 | 77265.08 | 未披露 | 定期报告 | 2023-02-10 |
| 2022-11-08 | 77268.59 | 未披露 | 定期报告 | 2022-10-31 |
| 2022-11-08 | 77268.61 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Exercise of common stock options and warrants
ModeX Acquisition
|
2022-09-30 |
| 2022-08-04 | 77195.96 | 未披露 | 定期报告 | 2022-07-28 |
| 2022-08-04 | 77193.66 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Exercise of common stock options and warrants
ModeX Acquisition
|
2022-06-30 |
| 2022-06-03 | 68194.90 | 未披露 | 定期报告 | 2022-05-23 |
| 2022-05-09 | 68152.52 | 未披露 | 定期报告 | 2022-04-25 |
| 2022-05-09 | 68148.30 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Exercise of common stock options and warrants
|
2022-03-31 |
| 2022-03-01 | 68145.53 | 未披露 | 定期报告 | 2022-02-25 |
| 2022-03-01 | 68142.72 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Exercise of common stock options and warrants
Conversion of 2025 convertible notes
|
2021-12-31 |
| 2021-10-28 | 68134.13 | 未披露 | 定期报告 | 2021-10-20 |
| 2021-10-28 | 68134.16 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Exercise of common stock options and warrants
|
2021-09-30 |
| 2021-07-29 | 68116.26 | 未披露 | 定期报告 | 2021-07-20 |
| 2021-07-29 | 68116.29 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Exercise of Common Stock options and warrants
Conversion of 2025 convertible notes
|
2021-06-30 |
| 2021-04-30 | 67015.66 | 未披露 | 定期报告 | 2021-04-26 |
| 2021-04-28 | 67015.33 | 未披露 | 定期报告 | 2021-04-20 |
| 2021-04-28 | 67015.32 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Exercise of Common Stock options and warrants
|
2021-03-31 |
| 2021-02-18 | 67003.54 | 未披露 | 定期报告 | 2021-02-08 |
| 2021-02-18 | 67003.57 | 未披露 |
更多>>
From December 31,2019 to December 31,2020
Exercise of Common Stock options and warrants
|
2020-12-31 |
| 2020-10-29 | 67000.00 | 未披露 | 定期报告 | 2020-10-20 |
| 2020-10-29 | 67000.03 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Exercise of Common Stock options and warrants
|
2020-09-30 |
| 2020-07-31 | 66983.10 | 未披露 | 定期报告 | 2020-07-20 |
| 2020-07-31 | 66982.88 | 未披露 | 定期报告 | 2020-06-30 |
| 2020-05-06 | 66982.85 | 未披露 | 定期报告 | 2020-05-01 |
| 2020-05-06 | 66982.88 | 未披露 | 定期报告 | 2020-03-31 |
| 2020-03-02 | 66982.85 | 未披露 | 定期报告 | 2020-02-15 |
| 2020-03-02 | 66982.88 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Exercise of Common Stock options and warrants
2025 convertible notes including share lending agreement
Sale of common stock
|
2019-12-31 |
| 2019-11-05 | 66560.08 | 未披露 | 定期报告 | 2019-10-30 |
| 2019-10-29 | 66560.10 | 未披露 | 定期报告 | 2019-10-29 |
| 2019-05-08 | 61560.10 | 未披露 | 定期报告 | 2019-04-24 |
| 2019-04-26 | 61612.38 | 未披露 | 定期报告 | 2019-04-22 |
| 2019-05-08 | 61560.10 | 未披露 |
更多>>
From December 31, 2018 to March 31, 2019
Exercise of Common Stock options and warrants
2025 convertible notes including share lending arrangement
|
2019-03-31 |
| 2019-03-01 | 61560.08 | 未披露 | 定期报告 | 2019-02-15 |
| 2019-03-01 | 58633.18 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Exercise of Common Stock options and warrants
Private placement
|
2018-12-31 |
| 2018-11-09 | 55982.75 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-07 | 55977.10 | 未披露 | 定期报告 | 2018-08-01 |
| 2018-08-07 | 55961.95 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-08 | 55947.38 | 未披露 | 定期报告 | 2018-05-01 |
| 2018-04-30 | 55947.36 | 未披露 | 定期报告 | 2018-04-18 |
| 2018-05-08 | 55947.38 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-01 | 55947.36 | 未披露 | 定期报告 | 2018-02-20 |
| 2018-03-01 | 55947.38 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Exercise of Common Stock options and warrants
Issuance of Treasury Stock in connection with OPKO Health Europe’s Contingent Consideration
|
2017-12-31 |
| 2017-11-08 | 55940.49 | 未披露 | 定期报告 | 2017-10-31 |
| 2017-11-08 | 55940.52 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-08 | 55940.49 | 未披露 | 定期报告 | 2017-08-01 |
| 2017-08-08 | 55940.52 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-04-28 | 55938.87 | 未披露 | 定期报告 | 2017-04-20 |
| 2017-04-28 | 55979.53 | 未披露 | 定期报告 | 2017-04-14 |
| 2017-05-10 | 55901.11 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-03-01 | 55822.20 | 未披露 | 定期报告 | 2017-02-20 |
| 2017-03-01 | 55798.93 | 未披露 |
更多>>
From December 31, 2015 to December 31, 2016
Exercise of Common Stock options and warrants
Issuance of Common Stock upon exchange of 2033 Senior Notes
Issuance of Common Stock for OPKO Renal earnout
Issuance of Common Stock for Transition Therapeutics purchase
|
2016-12-31 |
| 2016-11-07 | 55753.38 | 未披露 | 定期报告 | 2016-10-31 |
| 2016-11-07 | 55746.67 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-08-08 | 55038.09 | 未披露 | 定期报告 | 2016-07-27 |
| 2016-08-08 | 54771.48 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-09 | 54744.44 | 未披露 | 定期报告 | 2016-04-26 |
| 2016-05-09 | 54739.37 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-24 | 54584.01 | 未披露 | 定期报告 | 2016-03-17 |
| 2016-02-29 | 54569.68 | 未披露 | 定期报告 | 2016-02-16 |
| 2016-02-29 | 54506.81 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Exercise of Common Stock options and warrants
Issuance of Common Stock for EirGen purchase
Issuance of Common Stock for BRL purchase
Issuance of Common Stock upon exchange of 2033 Senior Notes
Issuance of Common Stock for OPKO Renal earnout
Issuance of Treasury Stock in connection with OPKO Health Europe’s Contingent Consideration
|
2015-12-31 |
| 2015-11-09 | 54501.17 | 未披露 | 定期报告 | 2015-10-30 |
| 2015-11-09 | 54483.13 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-08-05 | 46361.72 | 未披露 | 定期报告 | 2015-07-31 |
| 2015-08-05 | 46344.73 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-07-02 | 46329.15 | 未披露 | 定期报告 | 2015-06-02 |
| 2015-05-11 | 45842.47 | 未披露 | 定期报告 | 2015-04-30 |
| 2015-04-30 | 45839.36 | 未披露 | 定期报告 | 2015-04-20 |
| 2015-05-11 | 45806.92 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-02-27 | 45162.75 | 未披露 | 定期报告 | 2015-02-20 |
| 2015-02-27 | 43217.63 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Exercise of Common Stock options
Exercise of Common Stock warrants
Issuance of Common Stock for OPKO Uruguay Ltda.
Issuance of Common Stock upon exchange of 2033 Senior Notes
Issuance of Common Stock for Inspiro at 8.57
Issuance of Common Stock for OPKO Renal earnout
|
2014-12-31 |
| 2014-11-07 | 43414.46 | 未披露 | 定期报告 | 2014-10-31 |
| 2014-11-07 | 43165.04 | 未披露 | 定期报告 | 2014-09-30 |
| 2014-08-11 | 42919.60 | 未披露 | 定期报告 | 2014-08-01 |
| 2014-08-11 | 42585.75 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-05-09 | 41375.08 | 未披露 | 定期报告 | 2014-05-01 |
| 2014-04-25 | 41360.36 | 未披露 | 定期报告 | 2014-04-14 |
| 2014-05-09 | 41310.12 | 未披露 | 定期报告 | 2014-03-31 |
| 2014-03-03 | 41292.29 | 未披露 | 定期报告 | 2014-02-24 |
| 2014-03-03 | 41255.41 | 未披露 |
更多>>
from December 31, 2012 to December 31, 2013
Exercise of Common Stock options
Exercise of Common Stock warrants
Conversion of Series D Preferred Stock
Conversion of 3.00% convertible senior notes
Issuance of Common Stock in connection with OPKO Brazil acquisition at $6.73 per share
Issuance of Common Stock in connection with Cytochroma acquisition at $7.16 per share
Issuance of Common Stock in connection with PROLOR acquisition at $8.49 per
share and fair value of stock options and warrants exchanged
Issuance of Common Stock in connection with Farmadiet’s first Deferred Payment at $7.52 per share
Issuance of Treasury Stock in connection with Farmadiet’s Contingent Consideration at $11.60 per share
|
2013-12-31 |
| 2013-11-12 | 40798.95 | 未披露 | 定期报告 | 2013-10-31 |
| 2013-11-12 | 40661.09 | 未披露 |
更多>>
From December 31, 2012 to September 30, 2013
Exercise of Common Stock options
Exercise of Common Stock warrants
Conversion of Series D Preferred Stock
Conversion of 3.00% convertible senior notes
Issuance of Common Stock in connection with OPKO Brazil acquisition at $6.73 per share
Issuance of Common Stock in connection with Cytochroma acquisition at $7.16 per share
Issuance of Common Stock in connection with PROLOR acquisition at $8.49 per share and fair value of stock options and warrants exchanged
Issuance of Common Stock in connection with Farmadiet's first Deferred Payment at $7.52 per share
|
2013-09-30 |
| 2013-08-02 | 33739.74 | 未披露 | 定期报告 | 2013-08-02 |
| 2013-08-09 | 33681.17 | 未披露 | 定期报告 | 2013-07-31 |
| 2013-08-09 | 33675.20 | 未披露 |
更多>>
from December 31, 2012 to June 30, 2013
Exercise of Common Stock options
Exercise of Common Stock warrants
Conversion of Series D Preferred Stock
Issuance of Common Stock in connection with OPKO Brazil acquisition at $6.73 per share
Issuance of Common Stock in connection with Cytochroma acquisition at $7.16 per share
|
2013-06-30 |
| 2013-06-14 | 33674.25 | 未披露 | 定期报告 | 2013-06-11 |
| 2013-05-10 | 33673.73 | 未披露 | 定期报告 | 2013-04-30 |
| 2013-05-10 | 33653.59 | 未披露 |
更多>>
From December 31, 2012 to March 31, 2013
Exercise of Common Stock options
Exercise of Common Stock warrants
Conversion of Series D Preferred Stock
Issuance of Common Stock in connection with Silcon acquisition at $6.73 per share
Issuance of Common Stock in connection with Cytochroma acquisition at $7.16 per share
|
2013-03-31 |
| 2013-03-18 | 32425.77 | 未披露 | 定期报告 | 2013-03-08 |
| 2013-03-18 | 30556.08 | 112.90 |
更多>>
from December 31, 2011 to December 31, 2012
Exercise of Common Stock options
Exercise of Common Stock warrants
Adjustment of Common Stock
Issuance of Common Stock in connection with OURLab acquisition at $4.65 per share
|
2012-12-31 |
| 2012-11-09 | 29818.41 | 未披露 | 定期报告 | 2012-11-02 |
| 2012-11-09 | 29585.85 | 112.90 | 定期报告 | 2012-09-30 |
| 2012-08-09 | 29810.60 | 未披露 | 定期报告 | 2012-08-01 |
| 2012-08-09 | 29550.29 | 112.90 | 定期报告 | 2012-06-30 |
| 2012-05-10 | 29512.66 | 未披露 | 定期报告 | 2012-05-01 |
| 2012-05-10 | 29506.43 | 112.90 | 定期报告 | 2012-03-31 |
| 2012-03-15 | 29506.16 | 未披露 | 定期报告 | 2012-03-08 |
| 2012-03-15 | 29750.30 | 112.90 |
更多>>
from December 31, 2010 to December 31, 2011
Exercise of common stock options
Exercise of common stock warrants
Conversion of Series A preferred stock
Redemption of Series A preferred stock
Series D preferred stock conversion
Issuance of common stock at $3.75 per share
Issuance of common stock in connection with Claros acquisition at $5.04 per share
Issuance of common stock in connection with FineTech acquisition at $4.90 per share
|
2011-12-31 |
| 2011-11-09 | 29027.23 | 未披露 | 定期报告 | 2011-11-01 |
| 2011-11-09 | 28814.18 | 120.97 | 定期报告 | 2011-09-30 |
| 2011-08-08 | 28795.56 | 未披露 | 定期报告 | 2011-08-02 |
| 2011-08-08 | 28794.63 | 120.97 | 定期报告 | 2011-06-30 |
| 2011-05-10 | 28506.01 | 未披露 | 定期报告 | 2011-05-01 |
| 2011-05-10 | 28504.29 | 193.24 | 定期报告 | 2011-03-31 |
| 2011-03-16 | 25560.02 | 未披露 | 定期报告 | 2011-03-08 |
| 2011-03-16 | 25541.27 | 219.72 |
更多>>
from December 31, 2009 to December 31, 2010
Exercise of common stock options
Conversion of Series A preferred stock
Issuance of common stock to acquire Pharmacos Exakta at $1.46 per share
|
2010-12-31 |
| 2010-11-09 | 25535.63 | 未披露 | 定期报告 | 2010-11-03 |
| 2010-11-09 | 25531.32 | 216.47 | 定期报告 | 2010-09-30 |
| 2010-08-09 | 25531.27 | 未披露 | 定期报告 | 2010-08-05 |
| 2010-08-09 | 25527.99 | 219.72 | 定期报告 | 2010-06-30 |
| 2010-05-10 | 25523.19 | 未披露 | 定期报告 | 2010-05-03 |
| 2010-05-10 | 25522.94 | 219.72 | 定期报告 | 2010-03-31 |
| 2010-03-17 | 25540.61 | 未披露 | 定期报告 | 2010-03-08 |
| 2010-03-17 | 25371.74 | 223.56 |
更多>>
from DECEMBER 31, 2008 to DECEMBER 31, 2009
Series A preferred stock dividend
Conversion of Series A preferred Stock
Issuance of 8% Series D Preferred stock in private placement, including related parties at $24.80 per share
Exercise of common stock options
Exercise of common warrants
Issuance of common stock in private placement with related parties at $1.00 per share
Issuance of common stock in private placement, including related parties at $1.00 per share
Restricted stock grant
Purchase of shares at $3.55
|
2009-12-31 |
| 2009-03-16 | 19969.22 | 未披露 | 定期报告 | 2009-03-06 |
| 2009-03-16 | 19900.24 | 95.38 |
更多>>
from DECEMBER 31, 2007 to DECEMBER 31, 2008
Preferred stock dividend
Conversion of Series A preferred stock
Issuance of equity securities to acquire Vidus Ocular, Inc. at $1.65 per share
Correction of equity securities to Acuity
Exercise of common stock options
Exercise of common warrants
Issuance of common stock in private placement to related party at $1.84
Other disposition of assets for stock
|
2008-12-31 |
| 2008-03-31 | 18215.10 | 未披露 | 定期报告 | 2008-03-21 |
| 2008-03-31 | 17834.46 | 95.48 |
更多>>
from DECEMBER 31, 2006 to DECEMBER 31, 2007
Issuance of equity securities for net monetary assets at $0.43 per share
Conversion of Series A preferred stock
Preferred stock dividend
Issuance of equity securities to acquire Acuity Pharmaceuticals, Inc. at $2.65 per share
Issuance of common stock upon automatic conversion of Series C preferred stock
Issuance of equity securities to acquire Ophthalmic Technologies, Inc. at $2.57 per share
Issuance of equity securities to acquire software at $3.79 per share
Issuance of common stock in private placement to related party at $1.84 per share
Exercise of common stock options
Exercise of common warrants
|
2007-12-31 |
| 2007-03-22 | 3655.04 | 未披露 |
更多>>
an amendment to the Certificate of Incorporation of the Company increasing the number of shares of common stock which the Company is authorized to issue from 30,000,000 shares to 225,000,000 shares
|
2007-03-15 |
| 2007-03-22 | 1637.99 | 100.20 |
更多>>
from DECEMBER 31, 2005 to DECEMBER 31, 2006
Preferred stock converted to common stock
Preferred dividend (stock)
|
2006-12-31 |
| 2006-03-31 | 1687.81 | 未披露 | 定期报告 | 2006-03-29 |
| 2006-03-31 | 1633.38 | 95.28 |
更多>>
from DECEMBER 31, 2004 to DECEMBER 31, 2005
Preferred stock converted to common stock
Preferred dividend (stock)
|
2005-12-31 |
| 2005-04-22 | 1626.66 | 未披露 | 定期报告 | 2005-04-07 |
| 2005-04-22 | 1625.78 | 93.53 |
更多>>
from DECEMBER 31, 2003 to DECEMBER 31, 2004
Preferred stock converted to common stock
Preferred dividend (stock)
Exercise of stock options
Compensation related to grant of stock and options to board members
|
2004-12-31 |
| 2004-04-07 | 1584.86 | 未披露 | 定期报告 | 2004-03-15 |
| 2004-04-07 | 1570.36 | 89.06 |
更多>>
from DECEMBER 31, 2002 to DECEMBER 31, 2003
Preferred stock converted to common stock
Preferred dividend (stock)
Exercise of stock options
Issuance of shares previously recorded as issuance from Treasury Stock
Issuance of shares previously recorded as issuance from Treasury Stock
|
2003-12-31 |
| 2003-03-20 | 1618.45 | 未披露 | 定期报告 | 2003-03-17 |
| 2003-03-20 | 1567.33 | 82.80 |
更多>>
from DECEMBER 31, 2001 to DECEMBER 31, 2002
Preferred stock converted to common stock
Preferred dividend (stock)
|
2002-12-31 |
| 2002-03-27 | 1618.09 | 未披露 | 定期报告 | 2002-03-19 |
| 2002-03-27 | 1566.97 | 75.60 |
更多>>
from DECEMBER 31, 2000 to DECEMBER 31, 2001
Preferred stock converted to common stock
Preferred dividend (stock)
Proceeds from sale of Treasury stock
Purchase of Treasury stock
|
2001-12-31 |
| 2001-04-02 | 1615.08 | 未披露 | 定期报告 | 2001-03-27 |
| 2001-04-02 | 1614.67 | 71.84 |
更多>>
from DECEMBER 31, 1999 to DECEMBER 31, 2000
Preferred dividend (stock)
Preferred stock converted to common stock
related expenses of $1,999,000
Exercise of options and units
|
2000-12-31 |
| 2000-03-30 | 1278.18 | 未披露 | 定期报告 | 2000-03-27 |
| 2000-03-30 | 1037.75 | 72.89 |
更多>>
from DECEMBER 31, 1998 to DECEMBER 31, 1999
Preferred dividend (stock)
Preferred stock converted to common stock
Exercise of warrants
Exercise of options
Shares exchanged for technology
Issuance of compensatory stock
|
1999-12-31 |
| 1999-03-31 | 1025.63 | 未披露 | 定期报告 | 1999-03-30 |
| 1999-03-31 | 1020.98 | 74.69 |
更多>>
from DECEMBER 31, 1997 to DECEMBER 31, 1998
Preferred dividend (stock)
Preferred stock converted to common stock
Exercise of warrants
Exercise of options
Private placement
|
1998-12-31 |
| 1999-03-31 | 879.40 | 93.46 |
更多>>
from DECEMBER 31, 1996 to DECEMBER 31, 1997
Preferred dividend (stock)
Preferred stock converted to common stock
Exercise of unit purchase option
Exercise of warrants
Exercise of options
|
1997-12-31 |
From December 31, 2024 to December 31, 2025
Exercise of common stock options/vesting of restricted stock units
Repurchase of 2029 Convertible Notes
Shares repurchase
From June 30, 2025 to September 30, 2025
Share repurchase
From March 31, 2025 to June 30, 2025
Repurchase of 2029 Convertible Notes
Exercise of common stock options and vested restricted stock units
Share repurchase
From December 31, 2024 to March 31, 2025
Exercise of common stock options
From December 31, 2023 to December 31, 2024
Exercise of common stock options/vesting of restricted stock units
Shares repurchase
2025 Notes
From June 30, 2024 to September 30, 2024
Share repurchase
From March 31, 2024 to June 30, 2024
Exercise of common stock options and warrants
2025 convertible notes
From December 31, 2023 to March 31, 2024
2025 convertible notes
Share Repurchase
From December 31,2022 to December 31,2023
Exercise of common stock options and warrants
From June 30, 2023 to September 30, 2023
Exercise of common stock options and warrants
From March 31, 2023 to June 30, 2023
Exercise of common stock options and warrants
From June 30, 2022 to September 30, 2022
Exercise of common stock options and warrants
ModeX Acquisition
From March 31, 2022 to June 30, 2022
Exercise of common stock options and warrants
ModeX Acquisition
From December 31, 2021 to March 31, 2022
Exercise of common stock options and warrants
From December 31, 2020 to December 31, 2021
Exercise of common stock options and warrants
Conversion of 2025 convertible notes
From June 30, 2021 to September 30, 2021
Exercise of common stock options and warrants
From March 31, 2021 to June 30, 2021
Exercise of Common Stock options and warrants
Conversion of 2025 convertible notes
From December 31, 2020 to March 31, 2021
Exercise of Common Stock options and warrants
From December 31,2019 to December 31,2020
Exercise of Common Stock options and warrants
From June 30, 2020 to September 30, 2020
Exercise of Common Stock options and warrants
From December 31, 2018 to December 31, 2019
Exercise of Common Stock options and warrants
2025 convertible notes including share lending agreement
Sale of common stock
From December 31, 2018 to March 31, 2019
Exercise of Common Stock options and warrants
2025 convertible notes including share lending arrangement
from December 31, 2017 to December 31, 2018
Exercise of Common Stock options and warrants
Private placement
from December 31, 2016 to December 31, 2017
Exercise of Common Stock options and warrants
Issuance of Treasury Stock in connection with OPKO Health Europe’s Contingent Consideration
From December 31, 2015 to December 31, 2016
Exercise of Common Stock options and warrants
Issuance of Common Stock upon exchange of 2033 Senior Notes
Issuance of Common Stock for OPKO Renal earnout
Issuance of Common Stock for Transition Therapeutics purchase
from December 31, 2014 to December 31, 2015
Exercise of Common Stock options and warrants
Issuance of Common Stock for EirGen purchase
Issuance of Common Stock for BRL purchase
Issuance of Common Stock upon exchange of 2033 Senior Notes
Issuance of Common Stock for OPKO Renal earnout
Issuance of Treasury Stock in connection with OPKO Health Europe’s Contingent Consideration
from December 31, 2013 to December 31, 2014
Exercise of Common Stock options
Exercise of Common Stock warrants
Issuance of Common Stock for OPKO Uruguay Ltda.
Issuance of Common Stock upon exchange of 2033 Senior Notes
Issuance of Common Stock for Inspiro at 8.57
Issuance of Common Stock for OPKO Renal earnout
from December 31, 2012 to December 31, 2013
Exercise of Common Stock options
Exercise of Common Stock warrants
Conversion of Series D Preferred Stock
Conversion of 3.00% convertible senior notes
Issuance of Common Stock in connection with OPKO Brazil acquisition at $6.73 per share
Issuance of Common Stock in connection with Cytochroma acquisition at $7.16 per share
Issuance of Common Stock in connection with PROLOR acquisition at $8.49 per
share and fair value of stock options and warrants exchanged
Issuance of Common Stock in connection with Farmadiet’s first Deferred Payment at $7.52 per share
Issuance of Treasury Stock in connection with Farmadiet’s Contingent Consideration at $11.60 per share
From December 31, 2012 to September 30, 2013
Exercise of Common Stock options
Exercise of Common Stock warrants
Conversion of Series D Preferred Stock
Conversion of 3.00% convertible senior notes
Issuance of Common Stock in connection with OPKO Brazil acquisition at $6.73 per share
Issuance of Common Stock in connection with Cytochroma acquisition at $7.16 per share
Issuance of Common Stock in connection with PROLOR acquisition at $8.49 per share and fair value of stock options and warrants exchanged
Issuance of Common Stock in connection with Farmadiet's first Deferred Payment at $7.52 per share
from December 31, 2012 to June 30, 2013
Exercise of Common Stock options
Exercise of Common Stock warrants
Conversion of Series D Preferred Stock
Issuance of Common Stock in connection with OPKO Brazil acquisition at $6.73 per share
Issuance of Common Stock in connection with Cytochroma acquisition at $7.16 per share
From December 31, 2012 to March 31, 2013
Exercise of Common Stock options
Exercise of Common Stock warrants
Conversion of Series D Preferred Stock
Issuance of Common Stock in connection with Silcon acquisition at $6.73 per share
Issuance of Common Stock in connection with Cytochroma acquisition at $7.16 per share
from December 31, 2011 to December 31, 2012
Exercise of Common Stock options
Exercise of Common Stock warrants
Adjustment of Common Stock
Issuance of Common Stock in connection with OURLab acquisition at $4.65 per share
from December 31, 2010 to December 31, 2011
Exercise of common stock options
Exercise of common stock warrants
Conversion of Series A preferred stock
Redemption of Series A preferred stock
Series D preferred stock conversion
Issuance of common stock at $3.75 per share
Issuance of common stock in connection with Claros acquisition at $5.04 per share
Issuance of common stock in connection with FineTech acquisition at $4.90 per share
from December 31, 2009 to December 31, 2010
Exercise of common stock options
Conversion of Series A preferred stock
Issuance of common stock to acquire Pharmacos Exakta at $1.46 per share
from DECEMBER 31, 2008 to DECEMBER 31, 2009
Series A preferred stock dividend
Conversion of Series A preferred Stock
Issuance of 8% Series D Preferred stock in private placement, including related parties at $24.80 per share
Exercise of common stock options
Exercise of common warrants
Issuance of common stock in private placement with related parties at $1.00 per share
Issuance of common stock in private placement, including related parties at $1.00 per share
Restricted stock grant
Purchase of shares at $3.55
from DECEMBER 31, 2007 to DECEMBER 31, 2008
Preferred stock dividend
Conversion of Series A preferred stock
Issuance of equity securities to acquire Vidus Ocular, Inc. at $1.65 per share
Correction of equity securities to Acuity
Exercise of common stock options
Exercise of common warrants
Issuance of common stock in private placement to related party at $1.84
Other disposition of assets for stock
from DECEMBER 31, 2006 to DECEMBER 31, 2007
Issuance of equity securities for net monetary assets at $0.43 per share
Conversion of Series A preferred stock
Preferred stock dividend
Issuance of equity securities to acquire Acuity Pharmaceuticals, Inc. at $2.65 per share
Issuance of common stock upon automatic conversion of Series C preferred stock
Issuance of equity securities to acquire Ophthalmic Technologies, Inc. at $2.57 per share
Issuance of equity securities to acquire software at $3.79 per share
Issuance of common stock in private placement to related party at $1.84 per share
Exercise of common stock options
Exercise of common warrants
an amendment to the Certificate of Incorporation of the Company increasing the number of shares of common stock which the Company is authorized to issue from 30,000,000 shares to 225,000,000 shares
from DECEMBER 31, 2005 to DECEMBER 31, 2006
Preferred stock converted to common stock
Preferred dividend (stock)
from DECEMBER 31, 2004 to DECEMBER 31, 2005
Preferred stock converted to common stock
Preferred dividend (stock)
from DECEMBER 31, 2003 to DECEMBER 31, 2004
Preferred stock converted to common stock
Preferred dividend (stock)
Exercise of stock options
Compensation related to grant of stock and options to board members
from DECEMBER 31, 2002 to DECEMBER 31, 2003
Preferred stock converted to common stock
Preferred dividend (stock)
Exercise of stock options
Issuance of shares previously recorded as issuance from Treasury Stock
Issuance of shares previously recorded as issuance from Treasury Stock
from DECEMBER 31, 2001 to DECEMBER 31, 2002
Preferred stock converted to common stock
Preferred dividend (stock)
from DECEMBER 31, 2000 to DECEMBER 31, 2001
Preferred stock converted to common stock
Preferred dividend (stock)
Proceeds from sale of Treasury stock
Purchase of Treasury stock
from DECEMBER 31, 1999 to DECEMBER 31, 2000
Preferred dividend (stock)
Preferred stock converted to common stock
related expenses of $1,999,000
Exercise of options and units
from DECEMBER 31, 1998 to DECEMBER 31, 1999
Preferred dividend (stock)
Preferred stock converted to common stock
Exercise of warrants
Exercise of options
Shares exchanged for technology
Issuance of compensatory stock
from DECEMBER 31, 1997 to DECEMBER 31, 1998
Preferred dividend (stock)
Preferred stock converted to common stock
Exercise of warrants
Exercise of options
Private placement
from DECEMBER 31, 1996 to DECEMBER 31, 1997
Preferred dividend (stock)
Preferred stock converted to common stock
Exercise of unit purchase option
Exercise of warrants
Exercise of options